Life Science Intelligence

Join moderator Brandon Bendes in conversation with John Viscogliosi from Viscogliosi Bros, exploring the brothers’ entrepreneurial journey in medtech and their vision for the future. For more information watch this video https://www.youtube.com/watch?v=VjI2xPsGmF0&t=81s  

The Asia-Pacific (APAC) region is rapidly emerging as a powerhouse in the global medtech market. According to our  Global Market Analysis and Projections (MAP) Database , APAC is the second largest regional medtech market, boasting an estimated market size of $131 billion in 2023. This impressive figure is made more notable by the region’s rapid growth, with our medtech market intelligence team projecting APAC to experience nearly double the compound annual growth rate (CAGR) of both the United States and Europe. Specifically, APAC is projected to grow at a robust CAGR of 8.4% from 2023 to 2028. Growth Drivers Several key factors are contributing to growth. Primarily, the increasing population size, improved access to healthcare services, and an aging demographic play significant roles. These elements collectively drive demand for various medical procedures, particularly in core markets such as orthopedics, cardiology, and general surgery. High-Growth Procedures The core procedure ...

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, announce new partnerships, report positive clinical trial results, and much more on the road to  LSI Europe  ’25 in London (September 7–11). AliveCor Launched Kardia 12L, the company’s AI-powered, handheld 12-lead ECG system, in India following its successful U.S. debut. The CDSCO-approved device detects 35 cardiac determinations using a compact, reduced-lead design that enables faster, more accessible diagnosis in clinical settings. Amsel Medical Appointed George Adaniya to its Board of Directors, bringing decades of leadership across medical devices, pharma, aerospace, and industrial controls. His cross-sector experience and record of startup-to-exit success will support Amsel Medical’s growth and innovation strategy. Arsenal Medical Reported positive data from the EMBO-02 study evaluating NeoCast™, a next-generation liquid embolic agent, for chronic s...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funds, secure FDA clearances, appoint new board members, and much more on the road to  LSI Europe  ’25 in London (September 7–11). Acutus Medical Announced the acquisition of its AcQMap™ platform assets by EnChannel Medical to accelerate the development of next-generation non-contact mapping technologies for atrial fibrillation. The deal integrates key IP into EnChannel’s electrophysiology ecosystem, strengthening its mission to deliver precision, patient-specific AF treatment. Atmo Biosciences Received FDA 510(k) clearance for its Atmo Gas Capsule System, enabling U.S. commercialization of the company’s ingestible gas-sensing capsule for assessing gut motility. The system offers a radiation-free, clinically validated alternative for diagnosing conditions like gastroparesis and slow transit constipation. Cognito Therapeutics Completed enrollment in the pivotal HO...

The  global cardiac ablation devices market  is witnessing a significant transformation thanks to the emergence of pulsed field ablation (PFA) technology. Since its introduction in 2021, PFA has been rapidly changing the way atrial fibrillation (AFib) is treated, providing an alternative to traditional methods like radiofrequency (RF) and cryoablation. This innovative technology is now driving growth in the pulsed field ablation market, which is expected to see rapid expansion over the next few years. A New Era for Cardiac Ablation with Pulsed Field Ablation PFA uses non-thermal electroporation to selectively target myocardial cells while sparing non-cardiac tissue, offering several advantages over traditional ablation techniques. This technology significantly reduces procedure times — by 30% to 50% — resulting in better cost-efficiency and improved patient outcomes. Clinical data supports the notion that PFA may eventually match or even exceed the effectiveness of RF and cryo...

Under the direction of Founder and CEO Yosef Safi Harb, Happitech is rethinking cardiac monitoring with a next-generation smartphone-based platform, a CE-certified solution that enables long-term heart rate and rhythm tracking using only a smartphone, while also integrating with wearables and medical devices equipped with PPG sensors. By leveraging photoplethysmography (PPG) through a smartphone’s camera and flash, or any compatible sensor or wearable, Happitech delivers medical-grade insights anytime, anywhere. The platform is intended to support clinical decision-making, expand access, and reshape how atrial fibrillation (AFib) is detected and monitored today, and how other heart conditions are detected and monitored tomorrow. The Current Landscape Happitech’s foundational belief is that heart monitoring should be accessible, scalable, and effortless. Today, their CE-certified platform is already integrated into more than 50% of Dutch cardiology hospitals and supports long-term cardi...